Expression of stem cell factor receptor c-kit in human nontumoral and tumoral hepatic cells

European Journal of Gastroenterology and Hepatology

Volumn 21, Issue 10, 2009, Pages 1206-1211

  Mansuroglu, Tümen ^a   Baumhoer, Daniel ^a,b   Dudas, Jozsef ^a   Haller, Florian ^a   Cameron, Silke ^a   Lorf, Thomas ^a   Füzesi, László ^a   Ramadori, Giuliano ^a  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

^b UNIVERSITY OF BASEL   (Switzerland)

Author keywords

c kit; Hepatocellular carcinoma; Hepatocytes; Liver cirrhosis

Indexed keywords

MESSENGER RNA; STEM CELL FACTOR RECEPTOR; RNA;

ARTICLE; CANCER CELL; CANCER TISSUE; CELL PROLIFERATION; CONTROLLED STUDY; GENE EXPRESSION; GENETIC ANALYSIS; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER CELL; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER HOMOGENATE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTO ONCOGENE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; CARCINOMA, HEPATOCELLULAR; COMPLICATION; GENETICS; LIVER NEOPLASMS; METABOLISM; PATHOLOGY; PROCEDURES; TUMOR CELL CULTURE;

CARCINOMA, HEPATOCELLULAR; GENE EXPRESSION; HEPATOCYTES; HUMANS; LIVER CIRRHOSIS; LIVER NEOPLASMS; PROTO-ONCOGENE PROTEINS C-KIT; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, NEOPLASM; TUMOR CELLS, CULTURED;

EID: 70349745806     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: 10.1097/MEG.0b013e328317f4ef     Document Type: Article

References (32)

1. Sherman M. Hepatocellular carcinoma: epidemiology, risk factors, and screening. Semin Liver Dis 2005; 25:143-154. (Pubitemid 40781067)
2. Villanueva A, Newell P, Chiang DY, Friedman SL, Llovet JM. Genomics and signaling pathways in hepatocellular carcinoma. Semin Liver Dis 2007; 27:55-76. (Pubitemid 46269805)
3. Giannelli G, Napoli N, Antonaci S. Tyrosine kinase inhibitors: a potential approach to the treatment of hepatocellular carcinoma. Curr Pharm Des 2007; 13:3301-3304. (Pubitemid 350201685)
4. Ashman LK. The biology of stem cell factor and its receptor C-kit. Int J Biochem Cell Biol 1999; 31:1037-1051.
5. Smith MA, Pallister CJ, Smith JG. Stem cell factor: biology and relevance to clinical practice. Acta Haematol 2001; 105:143-150. (Pubitemid 32679596)
6. Ashman LK, Cambareri AC, To LB, Levinsky RJ, Juttner CA. Expression of the YB5.B8 antigen (c-kit proto-oncogene product) in normal human bone marrow. Blood 1991; 78:30-37.
7. Lorenzini S, Andreone P. Regenerative medicine and liver injury: what role for bone marrow derived stem cells? Curr Stem Cell Res Ther 2007; 2:83-88.
8. Roskoski R Jr. Signaling by Kit protein-tyrosine kinase: the stem cell factor receptor. Biochem Biophys Res Commun 2005; 337:1-13. (Pubitemid 41393751)
9. Reber L, Da Silva CA, Frossard N. Stem cell factor and its receptor c-Kit as targets for inflammatory diseases. Eur J Pharmacol 2006; 533:327-340. (Pubitemid 43340024)
10. Roskoski R Jr. Structure and regulation of kit protein-tyrosine kinase: the stem cell factor receptor. Biochem Biophys Res Commun 2005; 338:1307-1315. (Pubitemid 41608395)
11. Ramadori G, Fuzesi L, Grabbe E, Pieler T, Armbrust T. Successful treatment of hepatocellular carcinoma with the tyrosine kinase inhibitor imatinib in a patient with liver cirrhosis. Anti-Cancer Drugs 2004; 15:405-409. (Pubitemid 38526766)
12. Gospodarowicz MK, Miller D, Groome PA, Greene FL, Logan PA, Sobin LH. The process for continuous improvement of the TNM classification. Cancer 2004; 100:1-5. (Pubitemid 37553532)
13. Edmondson HA, Steiner PE. Primary carcinoma of the liver: a study of 100 cases among 48,900 necropsies. Cancer 1954; 7:462-503.
14. Yarden Y, Kuang WJ, Yang-Feng T, Coussens L, Munemitsu S, Dull TJ, et al. Human proto-oncogene c-kit: a new cell surface receptor tyrosine kinase for an unidentified ligand. EMBO J 1987; 6:3341-3351.
15. Butler SL, Dong H, Cardona D, Jia M, Zheng R, Zhu H, et al. The antigen for Hep Par 1 antibody is the urea cycle enzyme carbamoyl phosphate synthetase 1. Lab Invest 2008; 88:78-88.
16. Dudas J, Mansuroglu T, Moriconi F, Haller F, Wilting J, Lorf T, et al. Altered regulation of Prox1-gene-expression in liver tumors. BMC Cancer 2008; 8:92. (Pubitemid 351619151)
17. Pang RW, Poon RT. From molecular biology to targeted therapies for hepatocellular carcinoma: the future is now. Oncology 2007; 72 (Suppl 1): 30-44. (Pubitemid 350256663)
18. Arber DA, Tamayo R,Weiss LM. Paraffin section detection of the c-kit gene product (CD117) in human tissues: value in the diagnosis of mast cell disorders. Hum Pathol 1998; 29:498-504.
19. Lammie A, Drobnjak M, Gerald W, Saad A, Cote R, Cordon-Cardo C. Expression of c-kit and kit ligand proteins in normal human tissues. J Histochem Cytochem 1994; 42:1417-1425. (Pubitemid 24338014)
20. Matsuda R, Takahashi T, Nakamura S, Sekido Y, Nishida K, Seto M, et al. Expression of the c-kit protein in human solid tumors and in corresponding fetal and adult normal tissues. Am J Pathol 1993; 142:339-346. (Pubitemid 23026936)
21. Heinrich MC, Corless CL, Demetri GD, Blanke CD, von Mehren M, Joensuu H, et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 2003; 21:4342-4349. (Pubitemid 46621810)
22. Demetri GD, von MM, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts PJ, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002; 347:472-480. (Pubitemid 34879334)
23. Joensuu H, Fletcher C, Dimitrijevic S, Silberman S, Roberts P, Demetri G. Management of malignant gastrointestinal stromal tumours. Lancet Oncol 2002; 3:655-664. (Pubitemid 35314908)
24. Becker G, Schmitt-Graeff A, Ertelt V, Blum HE, Allgaier HP. CD117 (c-kit) expression in human hepatocellular carcinoma. Clin Oncol (R Coll Radiol) 2007; 19:204-208. (Pubitemid 46268578)
25. Potti A, Ganti AK, Tendulkar K, Chitajallu S, Sholes K, Koch M, Kargas S. HER-2/neu and CD117 (C-kit) overexpression in hepatocellular and pancreatic carcinoma. Anticancer Res 2003; 23:2671-2674. (Pubitemid 36897142)
26. Went PT, Dirnhofer S, Bundi M, Mirlacher M, Schraml P, Mangialaio S, et al. Prevalence of KIT expression in human tumors. J Clin Oncol 2004; 22:4514-4522. (Pubitemid 41185118)
27. Lee ES, Han EM, Kim YS, Shin BK, Kim CH, Kim HK, et al. Occurrence of c-kit + tumor cells in hepatitis B virus-associated hepatocellular carcinoma. Am J Clin Pathol 2005; 124:31-36. (Pubitemid 40944371)
28. Zhang F, Chen XP, Zhang W, Dong HH, Xiang S, Zhang WG, Zhang BX. Combined hepatocellular cholangiocarcinoma originating from hepatic progenitor cells: immunohistochemical and double-fluorescence immunostaining evidence. Histopathology 2008; 52:224-232.
29. Kara B, Doran F, Kara IO, Akkiz H, Sandikci M. Expression of c-kit protooncogen in hepatitis B virus-induced chronic hepatitis, cirrhosis and hepatocellular carcinoma: has it a diagnostic role? Int J Clin Pract 2008; 62:1206-1211.
30. Baccarani U, De SG, Adani GL, Donini A, Sainz-Barriga M, Lorenzin D, et al. Implication of stem cell factor in human liver regeneration after transplantation and resection. Growth Factors 2006; 24:107-110.
31. Krieg A, Schulte Am EJ, Schmelzle M, Tustas R, El-Karmi A, Hosch S, Knoefel WT. Stem cell factor levels do increase in patients subsequent to hepatectomy with the extent of parenchymal loss. Transplant Proc 2006; 38:3556-3558. (Pubitemid 44914087)
32. Ren X, Hogaboam C, Carpenter A, Colletti L. Stem cell factor restores hepatocyte proliferation in IL-6 knockout mice following 70% hepatectomy. J Clin Invest 2003; 112:1407-1418. (Pubitemid 38057694)